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Abstract
Objective: Rifampicin co-administration dramatically reduces plasma lopinavir concentrations. Studies in healthy volunteers
and HIV-infected patients showed that doubling the dose of lopinavir/ritonavir (LPV/r) or adding additional ritonavir offsets
this interaction. However, high rates of hepatotoxicity were observed in healthy volunteers. We evaluated the safety,
effectiveness and pre-dose concentrations of adjusted doses of LPV/r in HIV infected adults treated with rifampicin-based
tuberculosis treatment.
Methods: Adult patients on a LPV/r-based antiretroviral regimen and rifampicin-based tuberculosis therapy were enrolled.
Doubled doses of LPV/r or an additional 300 mg of ritonavir were used to overcome the inducing effect of rifampicin.
Steady-state lopinavir pre-dose concentrations were evaluated every second month.
Results: 18 patients were enrolled with a total of 79 patient months of observation. 11/18 patients were followed up until
tuberculosis treatment completion. During tuberculosis treatment, the median (IQR) pre-dose lopinavir concentration was
6.8 (1.1–9.2) mg/L and 36/47 (77%) were above the recommended trough concentration of 1 mg/L. Treatment was
generally well tolerated with no grade 3 or 4 toxicity: 8 patients developed grade 1 or 2 transaminase elevation, 1 patient
defaulted additional ritonavir due to nausea and 1 patient developed diarrhea requiring dose reduction. Viral loads after
tuberculosis treatment were available for 11 patients and 10 were undetectable.
Conclusion: Once established on treatment, adjusted doses of LPV/r co-administered with rifampicin-based tuberculosis
treatment were tolerated and LPV pre-dose concentrations were adequate.
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Introduction
In resource constrained settings the second-line antiretroviral
therapy (ART) regimen is based on ritonavir-boosted protease
inhibitors (PIs), usually co-formulated lopinavir/ritonavir (LPV/r).
Although ART reduces the risk of tuberculosis, incident cases
continue to occur on ART at rates higher than the general
population [1]. Rifampicin potently induces cytochrome (CYP)
3A4 and p-glycoprotein, resulting in more than a 90% reduction
in LPV concentrations [2]. Doubling the dose of LPV/r or adding
additional ritonavir (so that LPV:ritonavir=1:1) can overcome the
inducing effect of rifampicin [3,4]. Adjusting doses of PIs to
overcome induction by rifampicin resulted in very high rates of
hepatotoxicity in healthy volunteers [5–7], but we have demon-
strated that doubling the dose of LPV/r is relatively safe amongst
HIV-infected patients established on LPV/r-based ART [4]. The
safety and efficacy of adjusted dose LPV/r in HIV-infected
patients with tuberculosis is unclear. Standard tuberculosis
treatment includes isoniazid [8,9], which inhibits CYP 3A4 and
may attenuate the inducing effect of rifampicin on lopinavir
metabolism. Toxicity may also be different in patients receiving
combination tuberculosis treatment. We prospectively followed-up
patients on adjusted doses of LPV/r-based ART regimens who
were treated with rifampicin-based regimens for tuberculosis.
Methods
We prospectively enrolled HIV-infected adults older than 18
years from antiretroviral clinics in Cape Town, South Africa, who
were on concomitant treatment with rifampicin-based tuberculosis
treatment and a LPV/r-based ART regimen. The LPV/r-based
ART regimen forms part of second-line ART as recommended by
the WHO for developing countries. Doses of LPV/r were adjusted
in a non-randomised fashion by the treating clinicians as per
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either doubling the dose of the tablet formulation of LPV/r
(800 mg/200 mg 12 hourly) or adding additional ritonavir (LPV/r
400 mg/100 mg plus ritonavir 300 mg 12 hourly). The dosing
approach choice was left to the treating clinician. All formulations
used were from the originator pharmaceutical company, Abbott.
Patients were followed up monthly until 1 month after tuberculosis
treatment completion. During each study visit we measured
alanine transaminase (ALT). Treatment adherence was assessed
using a 3-day treatment recall questionnaire. Patients were asked
about the timing of their last LPV/r dose. All adverse events were
recorded and graded according to the grading system of the
Division of AIDS [10]. Lopinavir pre-dose concentrations were
measured every second month and were available within 2 weeks
of sampling in order to allow dose adjustment at the discretion of
the attending clinician. On the last study visit we measured the
viral load.
Plasma lopinavir concentrations were assayed as previously
described using liquid chromatography tandem mass spectrometry
[11]. The assay range for lopinavir was 0.05–20 mg/ml. Inter- and
intra-day coefficients of variation were below 10%. The laboratory
participates in the International Interlaboratory Control Program
of Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse
en Toxicologie (KKGT; Hague, The Netherlands). Lopinavir
concentrations reported as below the limit of quantification were
assigned a value of 0.025 mg/ml. We accounted for repeated
measures by calculating the mean lopinavir concentration in each
patient. We used the individual mean lopinavir concentrations to
calculate the median lopinavir concentration for each dosing
group. The HIV viral load was measured using the Abbot HIV
viral load assay with a lower limit of quantification of 40 copies per
ml. The study was approved by the University of Cape Town
Human Research Ethics Committee. Written informed consent
was obtained from every participant. The study was registered on
the Panafrican Clinical Trials registry (http://www.pactr.org) and
the South African National Clinical Trail Registry (http://www.
sanctr.gov.za) registry number DOH-27-1108-2594.
Results
We enrolled 18 treatment experienced patients, of whom 11
were female (Figure 1). Eleven patients received double dose
LPV/r and 7 received additional ritonavir. One patient was
changed from doubled doses of LPV/r to standard doses of LPV/
r plus additional ritonavir because of different dosing practices at
the health care facility where the patient was transferred. One
Figure 1. The profile of the study cohort.
doi:10.1371/journal.pone.0032173.g001
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according to weight: 12 patients received 600 mg, 5 received
450 mg and the dose was not recorded for 1 patient. In the
cohort, the median (IQR) age was 38.5 (33–47) yrs and the
median (IQR) CD4-count was 111 (41–181) cells/mm
3 (Table 1).
The median (IQR) month on tuberculosis treatment when
enrolled was 4 (2–5) with a total of 79 patient months of
observation. Eleven patients were followed up until after
tuberculosis treatment completion, 6 were lost to follow-up (3
in each dosing group) and 1 was still receiving tuberculosis
treatment when the study was ended. Of the 6 patients that were
lost to follow-up; 3 were not contactable, 2 abused alcohol and in
one health care staff identified adherence difficulties. In the 7
patients that were not followed up until tuberculosis treatment
completion, the median (IQR) time to tuberculosis treatment
completion was 1 (0–3.5) months.
Table 1. The baseline characteristics of the enrolled cohort.
Double dose LPV/r (800 mg/
200 mg) 12 hourly
(n=11)
Additional ritonavir
(400 mg/400 mg) hourly
(n=7)
Total
(n=18)
Weight
Median (IQR)
56 (53.5–59) kg 59.1 (61.2–70) kg 57 (54–63) kg
CD4-count
1
Median (IQR)
80 (37–424) cells/mm
3 145 (88–167) cells/mm
3 111(41–181) cells/mm
3
Viral load
2 ,40 copies per ml: n=3 ,40 copies per ml: n=3 ,40 copies per ml: n=6
$40 copies per ml: n=6 $40 copies per ml: n=4 $40 copies per ml: n=10
unknown: n=2 unknown: n=2
Duration on LPV/r prior to tuberculosis
treatment
4 (2–25) months 11 (9–31) months 10 (4–32) months
Median (IQR) (n=3) (n=5) (n=8)
Duration on tuberculosis treatment prior to
LPV/r initiation
2 (1–2) months 1 month 1.5 (1–2) months
Median (IQR)
3 (n=7) (n=2) (n=9)
Month of tuberculosis treatment when
enrolled, by patient
Patient 1=3 Patient 8=3 Median (IQR)=4 (2–5)
Patient 2=7 Patient 9=3
Patient 3=4 Patient 10=1
Patient 4=2 Patient 11=3
Patient 5=4 Patient 12=3
Patient 6=2 Patient 13=6
Patient 7=6 Patient 14=4
Median(IQR)=4 (2–4.5) Patient 15=4
Patient 16=4
Patient 17=5
Patient 18=2
Median (IQR)=4 (2.5–5)
Number of pharmacokinetic measurements
during study period, by patient
Patient 1=3 Patient 8=3 Median (IQR)=3 (2–4)
Patient 2=2 Patient 9=3
Patient 3=1 Patient 10=1
Patient 4=5 Patient 11=3
Patient 5=1 Patient 12=3
Patient 6=5 Patient 13=6
Patient 7=3 Patient 14=4
Median (IQR)=3 (2–4) Patient 15=4
Patient 16=4
Patient 17=5
Patient 18=2
Median (IQR)=3 (3–4)
1CD4-counts were collected from the clinical record. We recorded the last CD4-count prior to study enrolment.
2Viral load measurements were collected from the clinical record. We recorded the last viral load prior to study enrolment that was done within 6 months of tuberculosis
diagnosis and treatment.
3One patient was started on LPV/r-based ART and tuberculosis treatment on the same day in the double dose LPV/r group.
doi:10.1371/journal.pone.0032173.t001
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58 study visits, of which 47 were while patients were receiving
tuberculosis treatment. Lopinavir concentrations were measured
10 h22–18 h20 hours after the evening dose. During tuberculosis
treatment, the median (IQR) LPV pre-dose concentration across
all study visits was 6.8 (1.1–9.2) mg/L, and 36/47 (77%) measures
were above the recommended trough concentration of 1 mg/L
(Figure 2) [12,13]. The median lopinavir pre-dose concentration
was 6.2 mg/L in patients receiving additional ritonavir, 5.8 mg/L
in patients receiving double dose lopinavir, and 6.8 mg/L in
patients after tuberculosis therapy. We reduced the dose of LPV/r
from 4 to 3 tablets 12 hourly in a patient who developed
intolerable diarrhoea. During tuberculosis treatment 36/47 (77%)
LPV pre-dose concentrations were above the recommended
trough concentration of 1 mg/L [12,13]. Single lopinavir pre-
dose concentrations ,1 mg/L, with all others being .1 mg/mL
without dose adjustments, were observed during tuberculosis
treatment in 3 patients each in the additional ritonavir and double
dose LPV/r groups. The intra-individual variability in lopinavir
concentrations was most likely due to variability in adherence.
One patient in the additional ritonavir group had 2 lopinavir pre-
dose concentrations ,1 mg/L. She had an unsuppressed viral
load and a lopinavir pre-dose concentration ,1 mg/L after she
completed tuberculosis treatment and has since defaulted ART
care. Ten of the 11 patients that were followed up until
tuberculosis treatment completion had undetectable viral loads.
The median (IQR) lopinavir pre-dose concentration after
tuberculosis treatment was 6.8 (3.5–10.2) mg/L.
There were no adverse events of grade 3 or 4 toxicity. Ten
patients developed adverse events, 5 in each dosing group: 8
patients developed asymptomatic grade 1 or 2 transaminase
elevation, 1 patient defaulted additional ritonavir due to nausea
and 1 patient in the double dose group developed diarrhea
requiring dose reduction as noted above. The patient who received
a dose reduction had a suppressed viral load after tuberculosis
treatment completion. No transaminitis was recorded in the
patient who was HBsAg positive.
Discussion
We found that lopinavir pre-dose concentrations were adequate
in patients on rifampicin-based tuberculosis treatment. Most
patients had lopinavir pre-dose concentrations .1 mg/L with
adjusted LPV/r doses, confirming that adequate lopinavir
concentrations can be obtained in the presence of rifampicin-
based tuberculosis treatment by doubling the dose of LPV/r or
adding additional ritonavir. The isolated subtherapeutic measures
were most likely due to poor adherence.
The low rate of hepatotoxicity we observed is consistent with
our previous study of HIV-infected patients established on LPV/r
who were given rifampicin [4]. However, our previous findings
were limited because we did not study patients with tuberculosis,
other antitubercular drugs were not given, and follow up was brief.
The inhibitory effect of isoniazid on drug metabolizing enzymes
[8,9] in patients on combination tuberculosis treatment may
attenuate the inducing effect of rifampicin, thus potentially
resulting in higher lopinavir concentrations and altering the
Figure 2. Lopinavir concentrations of individual patients during the study period. The circles indicate lopinavir concentrations measured
while patients were receiving tuberculosis treatment, while the squares indicate lopinavir concentrations once tuberculosis treatment has been
completed.
doi:10.1371/journal.pone.0032173.g002
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predispose to hepatotoxicity [5–7]. In our cohort no hepatotoxicity
severe enough to warrant treatment discontinuation occurred, but
larger prospective studies need to confirm this. Proportionally
more patients in the additional ritonavir group developed adverse
events compared to the adjusted LPV/r group (5/7 compared to
5/11), but our study was not designed to detect adverse event
differences between the dosing approaches.
Data in patients receiving co-treatment with LPV/r and
rifampicin-based tuberculosis treatment is sparse as a limited
number of patients are currently receiving second line treatment.
L’homme et al retrospectively described their clinical experience of
combining LPV/r and rifampicin in 5 patients who received the
recommended increased dose of LPV/r, 2 of whom discontinued
treatment within 4 weeks due to acute adverse events [14] A
paediatric study found no significant difference in the proportions
of children with grade 3/4 transaminitis receiving tuberculosis
treatment and adjusted doses of LPV/r compared with children
on LPV/r alone [13].
Our study findings have several limitations. First, as most of our
study patients were enrolled once they were established on
tuberculosis treatment for several months, we may have under-
estimated toxicity by failing to identify patients who developed
early adverse events. Second, our attrition rate was relatively high.
These two limitations could have resulted in an under-estimation
of the toxicity of adjusted doses of LPV/r with rifampicin-based
antitubercular therapy. Third, the low lopinavir concentrations we
observed were likely due to missed doses that we did not detect as
we used self-report as an adherence measure, which is known to be
very insensitive. Fourth, due to the nature of the study, the time
post-dose of lopinavir concentrations varied between patients
(10 h22–18 h20 hours after the evening dose) increasing the
variability around our pre-dose lopinavir concentration estimates.
Lastly, our conclusions are limited by our small sample size.
The additional ritonavir dosing approach is complicated by the
increased pill burden and low temperature storage instructions.
Furthermore in our study and in a healthy volunteer study there
was a trend towards more toxicity in the additional ritonavir
dosing group, although neither study was adequately powered to
detect a difference in toxicity [3]. Nevertheless it is well established
that high doses of ritonavir are poorly tolerated. We therefore
suggest that double dose LPV/r be used in adequately powered
studies of tuberculosis patients in order to assess safety and
efficacy. Until further data are available it would be prudent to
monitor transaminases regularly during co-treatment. Our
approach has been to increase the LPV/r dose by 50% after a
week of anti-tuberculosis therapy and to double the dose after a
further week.
In conclusion, we found that once patients are established on
treatment adjusted doses of LPV/r co-administered with rifampi-
cin-based tuberculosis, treatment was tolerated and lopinavir pre-
dose concentrations were adequate. Further research is required to
better describe safety during the early period when tuberculosis
treatment is initiated in patients on LPV/r-based ART.
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